Clinical Trial Update | Olaparib plus bevacizumab first-line maintenance in ovarian cancer
5 Jun, 2023 | 13:07h | UTCOriginal Study: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer – New England Journal of Medicine
Original Study: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer – New England Journal of Medicine